133 results match your criteria bioidentical hormones


Compounded bioidentical hormone therapy: new recommendations from the 2020 National Academies of Sciences, Engineering, and Medicine.

Menopause 2021 Mar 8. Epub 2021 Mar 8.

University of California, San Diego, CA.

Abstract: Bioidentical hormones have the exact same chemical and molecular structure as hormones that are produced in the human body. Bioidentical hormones are available as FDA-approved hormone formulations. Nonapproved custom-compounded preparations are marketed as bioidentical, but content is uncertain. Read More

View Article and Full-Text PDF

Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.

J Clin Endocrinol Metab 2021 Jan 28. Epub 2021 Jan 28.

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Context: This mini-review provides an overview of menopausal hormone therapy (HT) and cardiovascular disease (CVD) risk, with a focus on the role of hormone formulation, dose, and route of delivery.

Methods: This summary is based on authors' knowledge in the field of menopausal HT and supplemented by a PubMed search using the terms "menopause hormone therapy", "transdermal", "estradiol", "conjugated estrogens", "bioidentical", "cardiovascular disease", "lipoproteins", "glucose", "progestogens", "low dose".

Results: Available evidence indicates that oral unopposed estrogens have a favorable effect on lipoprotein levels, glycemia, insulin and CVD risk, however the addition of progestogens blunts the lipid-related effects. Read More

View Article and Full-Text PDF
January 2021

Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 2.

Authors:
Angela DeRosa

Int J Pharm Compd 2021 Jan-Feb;25(1):14-17

Hormonal Health Institute, Scottsdale, Arizona.

This represents part two of a two-part article on the topic of gender bias within hormone replacement therapy and the well-orchestrated attempt by the pharmaceutical industry to eliminate bioidentical hormones, as well as to downplay the important role of compounding pharmacies in fulfilling the needs of women in this longstanding gender gap. Part one of this two-part article was published in the November/December 2020 issue of the International Journal of Pharmaceutical Compounding. That article discussed two of the four most prevalent reasons for this bias, Protecting the Bottom Line and Lack of Patent Protection. Read More

View Article and Full-Text PDF
January 2021

Bioidentical hormones.

Climacteric 2021 Feb 6;24(1):38-45. Epub 2021 Jan 6.

Departments of Obstetrics and Gynecology.

After the results of the Women's Health Initiative trials were published, patient and clinician interest in potential alternatives to conventional hormone therapy (HT) has grown. A commonly used alternative therapy involves custom-compounded steroid hormone preparations, formulated by compounding pharmacies. Many postmenopausal women consider the hormones as natural or bioidentical, in contrast to hormones used in conventional HT, which they consider synthetic. Read More

View Article and Full-Text PDF
February 2021

Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.

Ann Pharmacother 2020 Dec 21:1060028020982611. Epub 2020 Dec 21.

Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.

Objective: To review the efficacy, safety, and available literature regarding the novel combination bioidentical product Bijuva, or 17β-estradiol/progesterone (17β-E/P), for the treatment of moderate to severe menopausal symptoms in cisgender females with an intact uterus.

Data Sources: Literature searches of both PubMed (1966 to October 2020) and Google Scholar were conducted using search terms including , and .

Study Selection And Data Extraction: All articles with studies conducted in cisgender human females and in the English language were considered for review; 18 publications were included. Read More

View Article and Full-Text PDF
December 2020

Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 1.

Authors:
Angela DeRosa

Int J Pharm Compd 2020 Nov-Dec;24(6):466-470

Hormonal Health Institute, Scottsdale, Arizona.

Gender bias within hormone replacement therapy has been prevalent for decades, and the circumstances surrounding this bias continue to worsen. A billion-dollar industry has been built on dozens of testosterone replacement therapies and medications to treat andropause and erectile dysfunction for men; women have been less fortunate. This article discusses this bias and the well-orchestrated attempt by the pharmaceutical industry to eliminate bioidentical hormones, as well as to downplay the important role of compounding pharmacies in fulfilling the needs of women in this longstanding gender gap. Read More

View Article and Full-Text PDF
November 2020

Compounding for women's health: a compounder's perspective - need, regulations, and future.

Authors:
D Boomsma G Lahoud

Climacteric 2021 Feb 2;24(1):32-37. Epub 2020 Nov 2.

Custom Prescriptions of Lancaster LLC, Lancaster, PA, USA.

Compounding medicine involves various health-care professionals working together to produce medications that treat patient conditions including menopause and other women's health-related illnesses. These medications are compounded under the standards and guidelines mandated by individual state pharmacy boards, the US Food and Drug Administration, and other professional organizations. Contrary to commercial medications, the personalized medicine aspect of compounding medications ensures that the patient's allergies, doses, and drug delivery preferences are addressed during formulation. Read More

View Article and Full-Text PDF
February 2021

Compounded bioidentical menopausal hormone therapy - a physician perspective.

Authors:
C A Stuenkel

Climacteric 2021 Feb 19;24(1):11-18. Epub 2020 Oct 19.

University of California, San Diego, School of Medicine, La Jolla, CA, USA.

One of the defining moments of the 80-year evolution of menopausal hormone therapy (MHT) was the 2002 reveal of the initial results of the combined hormone therapy arm of the Women's Health Initiative (WHI) clinical trial. The exodus from regulatory approved MHT was prompt and profound and accompanied by a rapid acceleration of the compounding pharmacy 'bioidentical' hormone therapy industry. Compounders had recruited prescribers and promoted compounded bioidentical hormone therapy (cBHT) well before the WHI, yet the startling results provided a catalyst that enabled a leap in production of compounded hormones that were variably regulated, basically unstudied, and inconsistently labeled. Read More

View Article and Full-Text PDF
February 2021

Drugs for menopausal symptoms.

Authors:

Med Lett Drugs Ther 2020 08;62(1604):124-128

View Article and Full-Text PDF

The effect of bioidentical nanostructured progesterone in the in vitro culture of preantral follicles and oocyte maturation.

Cell Tissue Res 2020 Dec 21;382(3):657-664. Epub 2020 Jul 21.

Postgraduate Biotechnology, Potiguar University/Laureate International Universities, Av. Senador Salgado Filho, 1610, Lagoa Nova, Natal, Rio Grande do Norte, 59056-000, Brazil.

This study evaluated the effects of bioidentical nanostructured progesterone alone or in association with human chorionic gonadotropin (hCG) on the in vitro survival and development of preantral follicles (experiment 1) and oocyte maturation (experiment 2). Bioidentical hormones have a molecular structure identical with that of endogenous hormones; nanostructured substances refer to those reduced to a nanoscale. In experiment 1, fragments of goat ovarian tissue were cultured for 7 days in α-MEM alone or supplemented with nanoprogesterone (MEM + P4) or P4 and hCG (MEM + P4 + hCG). Read More

View Article and Full-Text PDF
December 2020

Transdermal delivery of bioidentical estrogen in menopausal hormone therapy: a clinical review.

Expert Opin Drug Deliv 2020 04 9;17(4):543-549. Epub 2019 Dec 9.

Division of Women's Health Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.

: The history of menopausal hormone therapy (HT) use has evolved over the years based on the influence of many factors, including availability and safety related to formulation and route of estrogen products. Given unexpected findings from the Women's Health Initiative (WHI) in the early 2000's that used oral conjugated equine estrogen, the desire for and research supporting transdermal estradiol products grew. Transdermal estrogen is now a popular and commonly used formulation for treating menopausal symptoms. Read More

View Article and Full-Text PDF

Hormone Therapy and Effects on Sporadic Alzheimer's Disease in Postmenopausal Women: Importance of Nomenclature.

J Alzheimers Dis 2020 ;73(1):23-37

Austin Health, Heidelberg Repatriation Hospital, Victoria, Australia.

Numerous observational studies have suggested that hormone therapy (HT) might protect postmenopausal women against cognitive decline and Alzheimer's disease (AD). However, because of the significant disparity between results, especially those between observational and randomized controlled trials (RCT), this postulate remains unproven. A significant contributing factor to these inconsistencies is the loose use of the generic definitions of estrogens and progestogens with most studies not delineating the clear differences between non-endogenous and endogenously identical (bioidentical) hormones, their molecular binding affinities and actions, and resultant metabolites. Read More

View Article and Full-Text PDF
January 2020

The dangers of compounded bioidentical hormone replacement therapy.

Br J Gen Pract 2019 11 31;69(688):540-541. Epub 2019 Oct 31.

Professor of Gynaecology, King's College London; Consultant Gynaecologist, Guy's and St Thomas' NHS Foundation Trust, London, UK.

View Article and Full-Text PDF
November 2019

The role of bioidentical hormone replacement therapy in anti-aging medicine: a review of the literature.

Int J Dermatol 2019 Oct 11. Epub 2019 Oct 11.

Moy-Fincher-Chipps Facial Plastics & Dermatology, Beverly Hills, CA, USA.

The changes in skin and overall appearance that occur with increasing age can be partly attributed to declining hormone levels. While hormonal deficiencies are most commonly associated with postmenopausal females, males are also subject to age-related testosterone decline and may benefit from replacement of deficient hormones. However, great disparities exist between the recommendations of scientific societies and actual use of hormone supplements in aging patients. Read More

View Article and Full-Text PDF
October 2019

Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies.

Menopause 2019 09;26(9):966-971

TherapeuticsMD, Boca Raton, FL.

Objectives: To analytically characterize the doses of estradiol and progesterone found in compounded combined forms of oral capsule and transdermal cream formulations, and determine the consistency of the hormone formulations within a batch.

Methods: Prescriptions for combined estradiol/progesterone capsules (0.5 and 100 mg, respectively) and creams (0. Read More

View Article and Full-Text PDF
September 2019

Colorectal cancer screening.

Authors:

Med Lett Drugs Ther 2019 Jul;61(1575):97-99

View Article and Full-Text PDF

A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.

Expert Rev Clin Pharmacol 2019 Aug 22;12(8):729-739. Epub 2019 Jul 22.

b TherapeuticsMD , Boca Raton , FL , USA.

: Many women seek treatment to alleviate menopausal vasomotor symptoms (VMS). Numerous women use combination compounded hormone therapy (CHT) to achieve the benefits of estrogen/progesterone for endometrial protection. TX-001HR is a combination of bioidentical 17β-estradiol (E2) and progesterone (P4) in a single capsule designed for continuous daily use to treat moderate to severe VMS. Read More

View Article and Full-Text PDF

Bioidentical hormone therapy in menopause: relevance in dermatology.

Dermatol Online J 2019 Jan 15;25(1). Epub 2019 Jan 15.

Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.

Hormone replacement therapy has been shown to be effective in alleviating menopausal symptoms. However, its use is controversial owing to potential health risks, such as thromboembolism and cancer. Bioidentical hormone therapy has recently become popular as an alternative to conventional hormone replacement therapy. Read More

View Article and Full-Text PDF
January 2019

Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.

J Womens Health (Larchmt) 2019 02 28;28(2):237-243. Epub 2018 Nov 28.

4 Department of Obstetrics and Gynecology, New York University School of Medicine , New York, New York.

Background: The Surveillance, Epidemiology, and End Result (SEER) database shows a variable increase in endometrial cancer incidence over time. The objective of this review was to examine published endometrial cancer rates and potential etiologies.

Methods: Endometrial cancer incidence was obtained from the SEER Program database from 1975 through 2014, and a test for trend in incidence was calculated. Read More

View Article and Full-Text PDF
February 2019

Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review.

Climacteric 2019 04 27;22(2):148-161. Epub 2018 Nov 27.

a Department of Obstetrics and Gynecology , University of Bern , Bern , Switzerland.

In women, body weight increases with age. Often menopausal hormone therapy (MHT) is blamed for enhancing this effect. In recent years, the debate on bioidentical MHT including micronized progesterone (MP) has increased. Read More

View Article and Full-Text PDF

Human versus non-human sex steroid use in hormone replacement therapies part 1: Preclinical data.

Mol Cell Endocrinol 2019 01 9;480:12-35. Epub 2018 Oct 9.

Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, USA.

Prior to 2002, hormone replacement therapy (HRT) was considered to be an important component of postmenopausal healthcare. This was based on a plethora of basic, epidemiological and clinical studies demonstrating the health benefits of supplementation with human sex steroids. However, adverse findings from the Women's Health Initiative (WHI) studies that examined the 2 major forms of HRT in use in the US at that time - Premarin (conjugated equine estrogens; CEE) and Prempro (CEE + medroxyprogesterone acetate; MPA), cast a shadow over the use of any form of HRT. Read More

View Article and Full-Text PDF
January 2019

Hormone Therapy and Breast Cancer: Emerging Steroid Receptor Mechanisms.

J Mol Endocrinol 2018 10 16;61(4):R133-R160. Epub 2018 Oct 16.

Department of Biochemistry, Stellenbosch University, Matieland, South Africa.

Although hormone therapy is widely used by millions of women to relieve symptoms of menopause, it has been associated with several side-effects such as coronary heart disease, stroke and increased invasive breast cancer risk. These side-effects have caused many women to seek alternatives to conventional hormone therapy, including the controversial custom-compounded bioidentical hormone therapy suggested to not increase breast cancer risk. Historically estrogens and the estrogen receptor were considered the principal factors promoting breast cancer development and progression, however, a role for other members of the steroid receptor family in breast cancer pathogenesis is now evident, with emerging studies revealing an interplay between some steroid receptors. Read More

View Article and Full-Text PDF
October 2018

Establishing a Rationale for Compounding Hormone Replacement Therapy.

Authors:
Bruce Biundo

Int J Pharm Compd 2018 May-Jun;22(3):190-195

Professional Compounding Centers of America (PCCA), Houston, Texas.

Why compound bioidentical hormones? Are there no similar commercial products? What is unique about the options compounding pharmacists offer compared with what is out in the marketplace? These are questions that physicians and other practitioners are asking, and it is very important that we have intelligent, well-thought answers when we respond. Times have changed, and the challenges we face today in marketing our compounded therapies are not the same as those of twenty years ago. Premarin is no longer at the top of the heap, and there are topical, commercial products that contain bioidentical estradiol, and capsules that contain the same progesterone that we use. Read More

View Article and Full-Text PDF
September 2018

Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls.

PLoS One 2018 16;13(5):e0197064. Epub 2018 May 16.

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.

Objective: By the 1990s it became popular for women to use hormone therapy (HT) to ease menopause symptoms. Bioidentical estrogen and progesterone are supplements whose molecular structures are identical to what is made in the human body, while synthetic supplements are ones whose structures are not. After the Women's Health Initiative found that the combined use of the synthetics conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) increased breast cancer risk, prescriptions for synthetic HT declined considerably. Read More

View Article and Full-Text PDF

Evidence on the use of progesterone in menopausal hormone therapy.

Authors:
S Mirkin

Climacteric 2018 08 9;21(4):346-354. Epub 2018 Apr 9.

a TherapeuticsMD , Boca Raton , FL , USA.

A need exists for a regulatory agency-approved hormone therapy (HT) with naturally occurring hormones combining progesterone (P4) and estradiol (E2), since no single product contains both endogenous hormones. Many women choose HT with P4 and millions of women around the world are using unapproved, poorly regulated compounded HT. The use of natural P4 in HT results, for the most part, in favorable outcomes without deleterious effects, as shown in clinical studies of postmenopausal women. Read More

View Article and Full-Text PDF

Prescribing Bioidentical Menopausal Hormone Therapy: A Survey of Physician Views and Practices.

J Womens Health (Larchmt) 2018 07 27;27(7):859-866. Epub 2018 Mar 27.

3 Department of Obstetrics and Gynecology, University of Kansas School of Medicine-Wichita , Wichita, Kansas.

Background: It is estimated that 1-2.5 million U.S. Read More

View Article and Full-Text PDF

The impact of micronized progesterone on breast cancer risk: a systematic review.

Climacteric 2018 04 31;21(2):111-122. Epub 2018 Jan 31.

c Clinic for Gynecological Endocrinology and Reproductive Medicine , RWTH University of Aachen , Aachen , Germany.

Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. The debate on bioidentical hormones including micronized progesterone has increased in recent years. Based on a systematic literature review on the impact of menopausal hormone therapy (MHT) containing micronized progesterone on the mammary gland, an international expert panel's recommendations are as follows: (1) estrogens combined with oral (approved) or vaginal (off-label use) micronized progesterone do not increase breast cancer risk for up to 5 years of treatment duration; (2) there is limited evidence that estrogens combined with oral micronized progesterone applied for more than 5 years are associated with an increased breast cancer risk; and (3) counseling on combined MHT should cover breast cancer risk - regardless of the progestogen chosen. Read More

View Article and Full-Text PDF

Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.

BMC Womens Health 2017 Oct 2;17(1):97. Epub 2017 Oct 2.

School of Anthropology, University of Arizona, 1009 E. South Campus Drive, Tucson, AZ, 85721, USA.

Background: In recent years, compounded bioidentical hormone therapy (CBHT) has emerged as a popular alternative to manufactured, FDA approved hormone therapy (HT)-despite concerns within the medical community and the availability of new FDA approved "bioidentical" products. This study aims to characterize the motivations for using CBHT in a U.S. Read More

View Article and Full-Text PDF
October 2017